Federal Circuit’s Decision in Allergan v. MSN: Implications for Obviousness-Type Double Patenting in U.S. Patent Law

The recent decision by the Federal Circuit in the case of Allergan v. MSN continues to shape the doctrine of obviousness-type double patenting, a key aspect of U.S. patent law intended to prevent the redundant patenting of the same invention or its obvious variations. This ruling not only underscores the inherent tensions between expiration-based interpretations and procedural adaptability but also highlights the ongoing evolution in judicial thinking on this doctrine. The decision’s implications are significant for patent holders and legal practitioners navigating the complexities of patent law. For further analysis, insights can be found in a detailed discussion by Jeremy Lowe at Leydig Voit.